Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2023 08:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

CHARLOTTESVILLE, Va., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
September 28, 2023 07:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Pre-registration for the LinkedIn Live event will begin on Thursday, September 28th Industry experts to discuss the need for non-abstinence-based therapies in Alcohol Use Disorder (AUD) ...
September 05, 2023 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

CHARLOTTESVILLE, Va., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...
August 28, 2023 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism

CHARLOTTESVILLE, Va., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
August 23, 2023 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

CHARLOTTESVILLE, Va., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
August 21, 2023 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Reported Positive Feedback from US and EU Regulatory Meetings Sale of Purnovate Significantly Reduces Cash Burn Rate Charlottesville, Va., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals,...
August 04, 2023 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float

CHARLOTTESVILLE, Va., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
July 11, 2023 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Provides Business Update Following Favorable Comments from US and EU Regulatory Meetings

CHARLOTTESVILLE, Va., July 11, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the...
June 01, 2023 09:00 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th

CHARLOTTESVILLE, Va., June 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
May 12, 2023 08:30 ET | Source: Adial Pharmaceuticals, Inc

Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Conducted meetings with U.S. and select European regulatory agencies Received Notice of Exercise and upfront cash of $0.45 million from Advocate for the sale of Purnovate assets and business Ended...